PRESS RELEASE




New postponement of the Offer Review Hearing

Lyon (France) – June 5, 2025 at 7:00 am CEST – PHAXIAM Therapeutics (Euronext: PHXM -
FR001400K4B1), a biopharmaceutical company ("the Company" or "PHAXIAM") developing innovative
treatments for severe and resistant bacterial infections, announces that the Lyon Commercial Court
(“Tribunal des activités économiques de Lyon”) decided, during a hearing held on June 4, 2025, to
postpone the offer review hearing and has set a new hearing date for Wednesday, June 11, 2025.

At the end of the bid examination hearing, whether a bid is accepted or not, the Lyon Commercial Court
will in any case soon pronounce the conversion of the judicial reorganization into judicial liquidation. In
this context, the Company will request the delisting of PHAXIAM shares from Euronext.

Furthermore, PHAXIAM draws investors’ attention to the fact that, given the Company’s level of
indebtedness, the disposal proceeds received in the event a bid is adopted would not allow for any
reimbursement of shareholders.



About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which
are responsible for many serious infections. The company is building on an innovative approach based on the use
of phages, natural bacteria-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most
resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired
infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAXIAM is listed on the Euronext regulated market in Paris (ISIN code: FR001400K4B1, ticker: PHXM). PHAXIAM
is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150
and Next Biotech indexes.

For more information, please visit www.phaxiam.com



Contacts

PHAXIAM NewCap
Thibaut du Fayet Mathilde Bohin / Dušan Orešanský
CEO Investor Relations
+33 4 78 74 44 38 Arthur Rouillé
investors@phaxiam.com Media Relations
+33 1 44 71 94 94
phaxiam@newcap.eu




1/1